EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(Amex: ILE) announced today that the Company will host an investor conference
call and webcast on Wednesday, October 22 at 4:30 PM Eastern Time to present
an analysis of the data from the Isolagen Therapy(TM) Phase III pivotal
studies (IT-R-005 and IT-R-006) for the treatment of nasolabial folds, or
wrinkles. On August 5, 2008, Isolagen reported positive top-line efficacy and
safety results from these two studies, which met all primary endpoints and
were highly statistically significant.
The call participants will include Declan Daly, Isolagen's CEO, Dr. Stacy
Smith, the Principal Investigator in the Phase III wrinkle studies and
Co-Principal Investigator in the Phase II/III acne study, and Dr. Jeanne Novak,
Clinical and Regulatory advisor to Isolagen.
A live webcast of the presentation will be accessible on www.isolagen.com.
To participate in the audio portion of the call, dial 1-800-299-0433 and enter
passcode 78803320. An archived replay of the conference call and webcast will
be available for 90 days on www.isolagen.com or by dialing 1-888-286-8010 and
entering passcode 63040312.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company
committed to developing and commercializing scientific advances and innovative
technologies. The company's technology platform includes the Isolagen
Process(TM), a cell processing system for skin and tissue rejuvenation which
is currently in clinical development for a broad range of aesthetic and
therapeutic applications including wrinkles, acne scars, burns and periodontal
disease. Isolagen also commercializes a scientifically-advanced line of
skincare systems through its majority-owned subsidiary, Agera(R) Laboratories,
Inc. For additional information, please visit www.isolagen.com.
Isolagen Forward Looking Statements
All statements in this news release that are not based on historical fact
are 'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act of 1995 and the provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. While management has based any forward-looking
statements contained herein on its current expectations, the information on
which such expectations were based may change. These forward-looking
statements rely on a number of assumptions concerning future events and are
subject to a number of risks, uncertainties, and other factors, many of which
are outside of our control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other factors
include, but are not necessarily limited to, those set forth under Item 1A
'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended
December 31, 2007, as updated in Item 1A. 'Risk Factors' in the Company's
Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly
changing environment, thus new or unforeseen risks may arise. Accordingly,
investors should not place any reliance on forward-looking statements as a
prediction of actual results. We disclaim any intention to, and undertake no
obligation to, update or revise any forward-looking statements. Readers are
also urged to carefully review and consider the other various disclosures in
the Company's Annual Report on Form 10-K for the year ended December 31, 2007,
as well as other public filings with the SEC since such date.
SOURCE Isolagen, Inc.
